Exome Sequencing for Developmental Delay: Where Payer Policy Still Lags the AAP
Short answer: The American Academy of Pediatrics now lists genome or exome sequencing, alongside chromosomal microarray, as a first-tier test for children with global developmental delay or intellectual disability. Payers have not uniformly followed. Policies such as UnitedHealthcare's, effective October 1, 2026, still add specialist-ordering and stepwise testing conditions that labs must plan around.
What the AAP changed
In a clinical report published in Pediatrics (volume 156, issue 1, DOI 10.1542/peds.2025-072219) and released on June 23, 2025, the AAP updated its guidance on the genetic evaluation of children with global developmental delay (GDD) or intellectual disability (ID). Contemporary Pediatrics reports that these conditions affect an estimated 1% to 3% of children worldwide.
The report describes a phenotype-driven starting point: developmental, medical, and family history, a physical exam for dysmorphic features, growth and neurologic findings, vision and hearing assessment, and brain MRI when syndromic features are present. If that evaluation is inconclusive, the report moves to a hypothesis-free, tiered testing strategy.
For laboratory and revenue-cycle teams, the practical shift is that the first genetic order for many of these children is no longer a microarray alone. It is a sequencing test, often paired with microarray, ordered by a clinician who may not be a geneticist.
The tiers, in detail
Per the Contemporary Pediatrics summary, tier 1 is genome or exome sequencing plus chromosomal microarray analysis. Tier 2 is fragile X CGG repeat testing and biochemical screening for inborn errors of metabolism. Tier 3 covers specialized evaluations: imprinting disorder testing, trinucleotide repeat analysis, mitochondrial DNA analysis, karyotyping, and genome reanalysis every one to two years.
The report also stresses pretest counseling. Families should discuss variants of uncertain significance and the possibility of incidental or secondary findings, including nonpaternity and disease predisposition. Labs that support pediatric ordering should expect more orders arriving with consent and counseling questions attached.
Importantly, the guidance is written for primary care pediatricians and, in the report's words as quoted by Contemporary Pediatrics, does not preclude further evaluation by neurologists, developmental pediatricians, and clinical geneticists. It is guidance, not a coverage determination.
Why the diagnostic yield argument matters to payers
GeneDx, a testing vendor, summarizes the AAP review as finding genomic sequencing has at least twice the diagnostic yield of chromosomal microarray in this population. That is a vendor characterization of the AAP evidence, and labs should cite the AAP report itself in appeals.
A 2026 retrospective clinical laboratory study in Frontiers in Neurology (Rigobello et al.) reported a genome sequencing diagnostic yield of 27.9% in 666 children with intellectual disability or developmental delay. The authors place published genome sequencing yields in a 21% to 41% range and report that about 8% of clinically relevant variants in their cohort would have been missed by exome sequencing combined with microarray.
These figures come from a single laboratory cohort and published ranges, not from a payer-accepted benchmark. They are useful for medical necessity narratives, but they do not replace the specific criteria a payer's policy lists.
Where payer policy still diverges
The UnitedHealthcare commercial policy for whole exome and whole genome sequencing (non-oncology), effective October 1, 2026, is a useful reference point. It covers WES or WGS for children with global developmental delay, or for moderate-to-profound intellectual disability diagnosed by age 18, when the individual has signs or symptoms of an undiagnosed disorder with a suspected genetic cause and results are expected to affect medical management. The presentation must not fit a well-delineated genetic syndrome for which targeted panel testing exists.
Three conditions stand out for ordering workflows. First, the test must be ordered by a medical geneticist, neonatologist, neurologist, immunologist, or developmental pediatrician, which excludes the general pediatrician the AAP report is written for. Second, chromosomal microarray or karyotype should be performed first if a specific genetic syndrome is suspected. Third, rapid WES, rapid WGS, and ultra-rapid WGS are described as unproven and not medically necessary in outpatient settings. For the broader UnitedHealthcare picture, see our analysis of UnitedHealthcare genetic testing prior authorization.
Policy language varies by payer and plan, and this article reviews one policy. Medicaid programs and other commercial plans publish their own criteria, so no single rule can be assumed.
Coverage on paper versus access in practice
In a June 24, 2026 Fast Company essay, Linda Genen, MD, MPH, GeneDx's chief medical officer, wrote that over 92% of commercial lives are under policies covering exome sequencing, per a 2025 analysis, and that genome sequencing coverage was expected to reach nearly 80% of commercial lives by mid-2026. She also noted several states added Medicaid coverage for exome sequencing in 2026.
The same essay cites a Nature publication for the finding that up to one in four families never complete testing, even after obtaining prior authorization, and argues that policies often conflict with AAP and ACMG guidance by requiring geneticist ordering, imposing age thresholds, or mandating stepwise prior testing. The author is an industry executive, so these are best read as an informed but interested perspective.
The gap this creates is operational, not just clinical. A test can be technically covered and still be practically inaccessible when the ordering clinician, documentation, or sequence of prior tests does not match policy text.
Vendors are building for the general pediatrician
On October 3, 2026, GeneDx announced Easy Order at the AAP 2026 conference. The company describes it as a streamlined workflow in its provider portal that reduces required data inputs so non-genetics specialists can order ExomeDx and chromosomal microarray tests. The announcement references the AAP guidance as its rationale.
Whether or not a lab uses a similar tool, the direction is clear: more sequencing orders will originate outside genetics clinics. That moves risk to front-end data capture, because a simplified order can still fail a payer's ordering-provider or documentation criteria.
What labs and billing teams should do now
Map each major payer's exome and genome policy against three fields: permitted ordering specialties, required prior testing, and setting-of-care limits such as the outpatient rapid sequencing language above. Build those checks into the intake workflow so a mismatch is caught before collection, not after denial. Our guides on prior authorization for genetic testing and genetic testing denials cover the workflow side.
Confirm diagnosis and code pairing for each order type. The UnitedHealthcare policy lists CPT 81415, 81416, 81425, and 81426 along with newer proprietary codes, and diagnosis selection should follow the clinical documentation; see ICD-10 codes for genetic testing.
Finally, prepare an appeal template that cites the AAP report directly, notes the reported diagnostic yield evidence with proper attribution, and addresses the payer's own criteria point by point. See the ScreenMyGene homepage for more resources for lab teams.
Frequently asked questions
Does the AAP require exome sequencing for every child with developmental delay?
No. The AAP report describes a tiered strategy that begins with a phenotype-driven evaluation, then lists genome or exome sequencing and chromosomal microarray as tier 1 tests. It is guidance for primary care pediatricians and does not preclude subspecialist evaluation by neurologists, developmental pediatricians, or clinical geneticists.
Does UnitedHealthcare cover exome sequencing for global developmental delay?
Its policy effective October 1, 2026 covers WES or WGS for global developmental delay or moderate to profound intellectual disability when criteria are met, including a suspected genetic cause and impact on management. The test must be ordered by a listed specialist, and microarray or karyotype may be required first if a specific syndrome is suspected.
Is rapid exome or genome sequencing covered in the outpatient setting?
Under the UnitedHealthcare policy effective October 1, 2026, rapid WES, rapid WGS, and ultra-rapid WGS are described as unproven and not medically necessary in outpatient settings. Other payers differ, so labs should check each policy for setting-of-care language before submitting an order or claim.
What CPT codes apply to exome and genome sequencing?
The UnitedHealthcare policy lists CPT 81415 for exome proband, 81416 for exome comparator, 81425 for genome proband, and 81426 for genome comparator, plus newer proprietary codes such as 0214U and 0215U. Code selection should follow the performing laboratory's test and the payer's published code list.
How often should genome data be reanalyzed?
The AAP tier 3 list includes genome reanalysis every one to two years for unresolved cases, as summarized by Contemporary Pediatrics. Reanalysis coverage was not addressed in the sources reviewed, so labs should confirm billing and authorization rules for reanalysis separately rather than assume they match the original order.
Educational disclaimer: This article is provided for informational and educational purposes only and is intended for laboratory, billing, and clinical operations professionals. It is not medical, legal, coverage, or reimbursement advice, and it does not recommend testing for any individual patient. Payer policies change frequently; verify requirements directly with each payer.
Sources: AAP clinical report, Pediatrics 156(1):e2025072219; Contemporary Pediatrics, "AAP updates guidance on genetic testing for developmental delay"; GeneDx blog, "AAP Recommends Exome & Genome Sequencing for Developmental Delay"; Rigobello et al., Frontiers in Neurology, 2026; UnitedHealthcare Commercial Medical Policy, Whole Exome and Whole Genome Sequencing (Non-Oncology), effective October 1, 2026; Fast Company, "Close the gap in pediatric genomic care," June 24, 2026; GeneDx press release, October 3, 2026.